查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2005690

生物防禦市場規模、佔有率、成長及全球產業分析：按類型和應用分類，區域洞察及2026-2034年預測

Biodefense Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 200 Pages | 商品交期: 請詢問到貨日

價格

生物防禦市場的成長要素

全球生物防禦市場預計在2025年達到162.3億美元，2026年成長至177.5億美元，並在2034年達到268.8億美元，預測期內複合年成長率（CAGR）為5.32%。 2025年，北美將以42.97%的市佔率引領全球市場，這主要得益於政府的大力投資、先進的醫療基礎設施以及生物技術和製藥公司的積極參與。

生物防禦是指旨在保護人類、生態系統和國家安全免受生物威脅的綜合戰略、技術和政策體系。這些威脅可能源自於自然發生的疫情、意外洩漏或蓄意的生物攻擊。生物防禦工作通常包括疫苗研發、病原體檢測系統、生物監測和緊急應變準備。日益成長的流行病、生物恐怖主義和新興感染疾病風險是推動該領域投資加速的主要動力。

俄烏衝突的影響

持續不斷的俄烏衝突加劇了全球對非對稱戰爭風險（包括生物製劑的使用）的認知。這種地緣政治情勢促使各國政府和國防機構加強生物防禦能力，並大幅增加對生物監測、快速診斷和醫療對策的投資。

此外，這場戰爭暴露了醫療衛生系統和供應鏈的脆弱性，促使各國加強疫苗和防護設備的國內生產。許多國家正在增加對病原體檢測技術和生物安全基礎設施研究的投入。因此，這場衝突間接地加速了國防費用，尤其是在北美和歐洲，因為各國政府都將重點放在應對疫情和加強國家安全上。

市場動態

市場促進因素

人們越來越意識到生物風險

人們對生物威脅的日益關注，以及各國政府的積極舉措，正在推動生物防禦市場的成長。世界各國政府都在大力投資疫苗儲備、病原體檢測系統和先進的生物監測技術。例如，2025年4月，帕森斯公司從美國海軍醫學研究司令部獲得了一份價值2400萬美元的契約，用於改進感染疾病檢測調查。

人工智慧 (AI)、機器學習、物聯網生物感測器和快速診斷等技術創新正在提高生物威脅偵測的速度和準確性。此外，一些突破性研究，例如密蘇里大學於 2023 年開發的奈米孔生物感測器，正在提升生物感測器在疾病早期檢測方面的性能。

市場限制因素

高昂的開發成本和監管挑戰

儘管需求強勁，生物防禦市場仍面臨許多挑戰。開發針對生物威脅的疫苗、診斷方法和治療方案需要大量的研究、臨床試驗和監管核准，導致研發成本非常高。

許多生物防禦產品針對罕見疾病，這使得進行大規模臨床試驗或證明其有效性變得困難。此外，嚴格的監管要求和法律責任風險也阻礙了一些公司投資該領域。如果沒有政府採購合約的保障，公司可能難以收回研發成本。

市場機遇

生物威脅日益加劇和技術進步

感染疾病爆發和疫情的威脅日益加劇，同時也帶來了巨大的發展機會。新冠肺炎疫情凸顯了快速檢測系統和可擴展疫苗生產平台的重要性。

人工智慧驅動的生物監測、基於物聯網的生物感測器和基因測序工具等新興技術，為早期發現和應對生物威脅創造了新的機會。此外，政府、研究機構和私人公司之間的合作正在加速創新，並加強全球應對生物威脅的準備。

生物防禦市場趨勢

先進技術的融合

技術創新正在改變生物防禦能力。人工智慧（AI）和機器學習正擴大應用於病原體識別、疫情預測和風險評估。

例如，2022 年，Tesseragen Biotechnology 與 Biomade 合作開發了一個人工智慧驅動的資料平台，以支援基於發酵的生物製造和應對生物威脅。

此外，生物技術和基因工程的進步正在推動新型疫苗平台、快速診斷測試和先進滅菌技術的研發。這些創新可望加強全球生物防禦基礎設施，並提高應對未來生物突發事件的準備能力。

細分分析

透過技術

以技術類別來看，市場包括紫外線、伽馬射線、冷等離子體和微波加熱。

預計到2025年，紫外線（UV）消毒領域將佔據最大的市場佔有率，並成為成長最快的領域。紫外線技術因其能有效去活化細菌、病毒和真菌等微生物而被廣泛用於消毒和殺菌。新冠疫情後，人們生物安全意識的提高以及對消毒技術需求的成長，正在推動其發展。

系統特定

市場可分為數位生物監測網路、預警系統、生物危害偵測系統、人工智慧輔助監測系統、生物感測器等。

由於生物危害檢測系統在快速識別生物威脅方面發揮至關重要的作用，預計到2026年，該細分市場將佔據35.19%的市場佔有率。同時，受攜帶式、高靈敏度病原體檢測設備需求不斷成長的推動，生物感測器細分市場預計將實現最快成長。

最終用戶

市場細分包括軍隊、國防安全保障、醫院和診所、製藥和生物技術公司以及病毒學研究機構。

預計到 2026 年，軍工領域將主導市場，佔 36.61% 的市場。這是因為軍方需要先進的防護裝備、疫苗和偵測系統來保護其人員免受生物威脅。

由於對疫苗研發、治療和診斷技術的投資增加，預計製藥和生技公司板塊將成長最快。

區域展望

北美洲

預計2025年，北美將引領生物防禦市場，規模達69.7億美元。美國憑藉強力的政府主導舉措和計畫（例如「生物盾牌計劃」和「生物醫學高級研究與發展局」）在區域市場中處於領先地位。預計到2026年，美國市場規模將達到74.1億美元。

歐洲

由於各國政府加大對生物安全和調查計畫的投入，預計歐洲將成為成長最快的區域市場。英國和德國等國正大力投資生物防禦技術，預計2026年，市場規模將分別達到7.1億美元和6.2億美元。

亞太地區

亞太地區正經歷強勁成長，這主要得益於公眾對健康問題的日益關注以及對疾病監測系統投資的不斷增加。預計2026年，該地區市場規模將分別達到：中國34.8億美元、印度6.5億美元和日本4.4億美元。

中東、非洲和拉丁美洲

由於人們對生物威脅的認知不斷提高、政府主導的舉措以及生物技術研究活動的擴大，預計這些地區將經歷適度成長。

儘管面臨研發成本高和監管複雜等挑戰，但全球應對生物威脅的準備工作不斷加強，將繼續推動對疫苗、檢測系統和生物監測技術的需求。預計北美將繼續保持主導地位，但歐洲和亞太地區將在未來十年成為主要的成長區域。

按細分市場和技術分類

  • 紫外線
  • 伽瑪射線
  • 低溫等離子體
  • 微波加熱
  • 其他

系統特定

  • 數位生物監測網路
  • 預警系統
  • 生物危害檢測系統
  • 人工智慧監控系統
  • 生物感測器
  • 其他

最終用戶

  • 軍隊
  • 國防安全保障
  • 醫院和診所
  • 製藥和生物技術公司
  • 病毒學研究所

按地區

  • 北美（按技術、系統、最終用戶和國家分類）
    • 美國（最終用戶）
    • 加拿大（最終用戶）
  • 歐洲（按技術、系統、最終用戶和國家分類）
    • 英國（最終用戶）
    • 德國（最終用戶）
    • 法國（最終用戶）
    • 俄羅斯（最終用戶）
    • 其他歐洲國家（按最終用戶分類）
  • 亞太地區（按技術、系統、最終用戶和國家分類）
    • 中國（最終用戶）
    • 印度（最終用戶）
    • 日本（最終用戶）
    • 韓國（最終用戶）
    • 其他亞太地區（按最終用戶分類）
  • 中東和非洲（按技術、系統、最終用戶和國家分類）
  • 伊朗（最終用戶）
    • 以色列（最終用戶）
    • 沙烏地阿拉伯（最終用戶）
    • 土耳其（最終用戶）
    • 其他中東和非洲地區（按最終用戶分類）
  • 拉丁美洲（按技術、系統、最終用戶和國家分類）
    • 巴西（最終用戶）
    • 阿根廷（最終用戶）
    • 墨西哥（最終用戶）
    • 其他拉丁美洲國家（按最終用戶分類）

目錄

第1章：引言

第2章執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 產業主要趨勢：重大合約和協議、合併、收購和合作。
  • 最新技術進展
  • 波特五力分析
  • 供應鏈分析
  • 定性分析－新冠疫情的影響：全球生物防禦市場
  • 監管分析：全球生物防禦市場

第5章：全球生物防禦市場分析、洞察與預測（2021-2034年）

  • 主要發現和定義
  • 市場分析、洞察與預測：按技術分類
    • 微波加熱
    • 紫外線
    • 伽瑪射線
    • 冷等離子
    • 其他
  • 市場分析、洞察與預測：按系統分類
    • 數位生物監測網路
    • 預警系統
    • 生物危害檢測系統
    • 人工智慧輔助監控系統
    • 生物感測器
    • 其他
  • 市場分析、洞察與預測：按最終用戶分類
    • 軍隊
    • 國防安全保障
    • 醫院和診所
    • 製藥和生物技術公司
    • 病毒學研究所
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 中東和非洲
    • 拉丁美洲

第6章：北美生物防禦市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲生物防禦市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 俄羅斯
    • 其他歐洲國家

第8章：亞太生物防禦市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太國家

第9章：中東和非洲生物防禦市場分析、洞察與預測（2021-2034年）

  • 國家
    • 伊朗
    • 以色列
    • 沙烏地阿拉伯
    • 土耳其
    • 其他中東和非洲國家

第10章：拉丁美洲生物防禦市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 阿根廷
    • 墨西哥
    • 其他拉丁美洲國家

第11章 競爭分析

  • 全球市場排名分析（2025 年）
  • 競爭對手儀錶板

第12章：公司簡介

  • AirBoss Defense Group, Inc.（US）
  • Bioquell, An Ecolab Solution（US）
  • Bio-Rad Laboratories, Inc.（US）
  • BlueDot Inc.（Canada）
  • E4life Srl（Australia）
  • Emergent BioSolutions Inc.（US）
  • SIGA Technologies, Inc.（US）
  • Dynavax Technologies（US）
  • Alnylam Pharmaceuticals, Inc.（US）
  • Ichor Medical Systems Inc.（US）
  • Bavarian Nordic A/S（Denmark）
  • SKAN AG（Switzerland）
  • Smiths Detection Group Ltd（UK）
  • Parsons Corporation（US）
Product Code: FBI113684

Growth Factors of biodefense Market

The global biodefense market was valued at USD 16.23 billion in 2025 and is projected to grow to USD 17.75 billion in 2026, reaching USD 26.88 billion by 2034, registering a CAGR of 5.32% during the forecast period. In 2025, North America dominated the global market with a 42.97% share, driven by strong government investment, advanced healthcare infrastructure, and active participation from biotechnology and pharmaceutical companies.

Biodefense refers to a comprehensive system of strategies, technologies, and policies designed to protect populations, ecosystems, and national security from biological threats. These threats may arise from natural outbreaks, accidental releases, or deliberate biological attacks. Biodefense initiatives typically include vaccine development, pathogen detection systems, biosurveillance, and emergency response preparedness. The growing risks of pandemics, bioterrorism, and emerging infectious diseases are major factors accelerating investments in this sector.

Impact of the Russia-Ukraine Conflict

The ongoing Russia-Ukraine conflict has heightened global awareness of unconventional warfare risks, including the potential use of biological agents. This geopolitical situation has encouraged governments and defense organizations to strengthen biodefense capabilities and invest more heavily in biosurveillance, rapid diagnostics, and medical countermeasures.

The war has also exposed vulnerabilities in healthcare systems and supply chains, pushing nations to enhance domestic production of vaccines and protective equipment. Many countries have increased research funding for pathogen detection technologies and biosecurity infrastructure. Consequently, the conflict has indirectly accelerated biodefense spending, particularly in North America and Europe, as governments focus on strengthening pandemic preparedness and national security.

Market Dynamics

Market Drivers

Increasing Awareness of Biological Risks

Growing awareness of biological threats, combined with government initiatives, is driving biodefense market growth. Governments worldwide are investing heavily in vaccine stockpiling, pathogen detection systems, and advanced biosurveillance technologies. For example, in April 2025, Parsons Corporation received a USD 24 million contract from the Naval Medical Research Command to improve infectious disease detection research.

Technological innovations such as artificial intelligence (AI), machine learning, IoT-enabled biosensors, and rapid diagnostics are improving the speed and accuracy of biological threat detection. In addition, research breakthroughs-such as the nanopore-based biosensor developed at the University of Missouri in 2023-are advancing biosensor capabilities for early disease detection.

Market Restraints

High Development Costs and Regulatory Challenges

Despite strong demand, the biodefense market faces several challenges. Developing vaccines, diagnostics, and therapeutics for biological threats requires extensive research, clinical trials, and regulatory approvals, resulting in very high R&D costs.

Many biodefense products target rare diseases, making it difficult to conduct large clinical trials or demonstrate product effectiveness. Additionally, strict regulatory requirements and liability risks discourage some companies from investing in this sector. Without guaranteed government procurement contracts, companies may struggle to recover development costs.

Market Opportunities

Rising Biological Threats and Technological Advancements

The increasing occurrence of infectious diseases and pandemic threats presents significant growth opportunities. The COVID-19 pandemic demonstrated the importance of rapid detection systems and scalable vaccine production platforms.

Emerging technologies such as AI-powered biosurveillance, IoT-based biosensors, and genomic sequencing tools are creating new opportunities for early detection and response to biological threats. Furthermore, collaboration between governments, research institutions, and private companies is accelerating innovation and improving global preparedness against biological hazards.

Biodefense Market Trends

Integration of Advanced Technologies

Technological innovation is transforming biodefense capabilities. Artificial intelligence and machine learning are increasingly used for pathogen identification, outbreak prediction, and risk assessment.

For instance, TeselaGen Biotechnology partnered with BioMADE in 2022 to develop AI-driven data platforms that support fermentation-based biomanufacturing and biological threat response.

Additionally, advancements in biotechnology and genetic engineering are enabling the development of new vaccine platforms, rapid diagnostic tests, and advanced sterilization technologies. These innovations are expected to strengthen global biodefense infrastructure and improve preparedness against future biological emergencies.

Segmentation Analysis

By Technology

Based on technology, the market includes UV light, gamma radiation, cold plasma, microwave heating, and others.

The UV light segment accounted for the largest share in 2025 and is expected to be the fastest-growing segment. UV technology is widely used for sterilization and decontamination because it effectively inactivates microorganisms such as bacteria, viruses, and fungi. Increasing biosecurity awareness and demand for disinfection technologies after the COVID-19 pandemic are driving its growth.

By System

The market is categorized into digital biosurveillance networks, early warning systems, biohazard detection systems, AI-assisted surveillance systems, biosensors, and others.

The biohazard detection systems segment is projected to account for 35.19% of the market share in 2026, as these systems play a crucial role in identifying biological threats quickly. Meanwhile, the biosensors segment is expected to grow the fastest due to increasing demand for portable and highly sensitive pathogen detection devices.

By End User

The market is segmented into military forces, homeland security, hospitals & clinics, pharmaceutical & biotech companies, and virological research institutes.

The military forces segment is expected to dominate the market with a 36.61% share in 2026, as armed forces require advanced protective equipment, vaccines, and detection systems to safeguard personnel from biological threats.

The pharmaceutical & biotech companies segment is projected to be the fastest-growing due to rising investments in vaccine development, therapeutics, and diagnostic technologies.

Regional Outlook

North America

North America dominated the biodefense market in 2025, reaching USD 6.97 billion. The United States leads the regional market due to strong government initiatives and programs such as Project BioShield and BARDA. The U.S. market is projected to reach USD 7.41 billion by 2026.

Europe

Europe is expected to be the fastest-growing regional market due to increasing government funding for biosecurity and research programs. Countries such as the U.K. and Germany are investing heavily in biodefense technologies, with projected market sizes of USD 0.71 billion and USD 0.62 billion respectively by 2026.

Asia Pacific

Asia Pacific is witnessing strong growth due to rising public health concerns and increased investments in disease surveillance systems. By 2026, the market size is projected to reach USD 3.48 billion in China, USD 0.65 billion in India, and USD 0.44 billion in Japan.

Middle East & Africa and Latin America

These regions are expected to experience moderate growth due to increasing awareness of biological threats, government initiatives, and expanding biotechnology research activities.

Competitive Landscape

The biodefense market is highly competitive, with major players focusing on innovation, partnerships, and acquisitions to strengthen their positions. Key companies include AirBoss Defense Group, Emergent BioSolutions, SIGA Technologies, Bio Rad Laboratories, and Smiths Detection.

Recent developments include vaccine approvals, government procurement contracts, and collaborations aimed at strengthening global biological threat response capabilities.

Conclusion

The biodefense market is expected to grow steadily from USD 16.23 billion in 2025 to USD 26.88 billion by 2034, driven by rising concerns about pandemics, biological warfare, and emerging infectious diseases. Increasing government investments, technological innovations such as AI-based biosurveillance and advanced biosensors, and growing public-private collaborations are shaping the future of the industry.

While challenges such as high R&D costs and regulatory complexities remain, expanding global preparedness for biological threats will continue to drive demand for vaccines, detection systems, and biosurveillance technologies. North America will likely maintain its leadership, while Europe and Asia Pacific emerge as key growth regions in the coming decade.

By Segmentation By Technology

  • UV Light
  • Gamma Radiation
  • Cold Plasma
  • Microwave Heating
  • Others

By System

  • Digital Biosurveillance Networks
  • Early Warning Systems
  • Biohazard Detection Systems
  • AI-Assisted Surveillance System
  • Biosensors
  • Others

By End User

  • Military Forces
  • Homeland Security
  • Hospitals & Clinics
  • Pharmaceutical & Biotech Companies
  • Virological Research Institutes

By Region

  • North America (By Technology, By System, By End User, By Country)
    • U.S. (By End User)
    • Canada (By End User)
  • Europe (By Technology, By System, By End User, By Country)
    • U.K. (By End User)
    • Germany (By End User)
    • France (By End User)
    • Russia (By End User)
    • Rest of Europe (By End User)
  • Asia Pacific (By Technology, By System, By End User, By Country)
    • China (By End User)
    • India (By End User)
    • Japan (By End User)
    • South Korea (By End User)
    • Rest of Asia Pacific (By End User)
  • Middle East & Africa (By Technology, By System, By End User, By Country)
  • Iran (By End User)
    • Israel (By End User)
    • Saudi Arabia (By End User)
    • Turkey (By End User)
    • Rest of Middle East & Africa (By End User)
  • Latin America (By Technology, By System, By End User, By Country)
    • Brazil (By End User)
    • Argentina (By End User)
    • Mexico (By End User)
    • Rest of Latin America (By End User)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Key Industry Developments - Key Contracts & Agreements, Mergers, Acquisitions and Partnerships
  • 4.2. Latest Technological Advancements
  • 4.3. Porters Five Forces Analysis
  • 4.4. Supply Chain Analysis
  • 4.5. Qualitative Insights - Impact of COVID-19 Pandemic on Global Biodefense Market
  • 4.6. Regulatory Analysis on Global Biodefense Market

5. Global Biodefense Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Definition
  • 5.2. Market Analysis, Insights and Forecast - By Technology
    • 5.2.1. Microwave Heating
    • 5.2.2. UV Light
    • 5.2.3. Gamma Radiation
    • 5.2.4. Cold Plasma
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By System
    • 5.3.1. Digital Biosurveillance Networks
    • 5.3.2. Early Warning Systems
    • 5.3.3. Biohazard Detection Systems
    • 5.3.4. AI-Assisted Surveillance System
    • 5.3.5. Biosensors
    • 5.3.6. Others
  • 5.4. Market Analysis, Insights and Forecast - By End User
    • 5.4.1. Military Forces
    • 5.4.2. Homeland Security
    • 5.4.3. Hospitals & Clinics
    • 5.4.4. Pharmaceutical & Biotech Companies
    • 5.4.5. Virological Research Institutes
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Middle East & Africa
    • 5.5.5. Latin America

6. North America Biodefense Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Technology
    • 6.1.1. Microwave Heating
    • 6.1.2. UV Light
    • 6.1.3. Gamma Radiation
    • 6.1.4. Cold Plasma
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By System
    • 6.2.1. Digital Biosurveillance Networks
    • 6.2.2. Early Warning Systems
    • 6.2.3. Biohazard Detection Systems
    • 6.2.4. AI-Assisted Surveillance System
    • 6.2.5. Biosensors
    • 6.2.6. Others
  • 6.3. Market Analysis, Insights and Forecast - By End User
    • 6.3.1. Military Forces
    • 6.3.2. Homeland Security
    • 6.3.3. Hospitals & Clinics
    • 6.3.4. Pharmaceutical & Biotech Companies
    • 6.3.5. Virological Research Institutes
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
      • 6.4.1.1. Market Analysis, Insights and Forecast - By End User
        • 6.4.1.1.1. Military Forces
        • 6.4.1.1.2. Homeland Security
        • 6.4.1.1.3. Hospitals & Clinics
        • 6.4.1.1.4. Pharmaceutical & Biotech Companies
        • 6.4.1.1.5. Virological Research Institutes
    • 6.4.2. Canada
      • 6.4.2.1. Market Analysis, Insights and Forecast - By End User
        • 6.4.2.1.1. Military Forces
        • 6.4.2.1.2. Homeland Security
        • 6.4.2.1.3. Hospitals & Clinics
        • 6.4.2.1.4. Pharmaceutical & Biotech Companies
        • 6.4.2.1.5. Virological Research Institutes

7. Europe Biodefense Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Technology
    • 7.1.1. Microwave Heating
    • 7.1.2. UV Light
    • 7.1.3. Gamma Radiation
    • 7.1.4. Cold Plasma
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By System
    • 7.2.1. Digital Biosurveillance Networks
    • 7.2.2. Early Warning Systems
    • 7.2.3. Biohazard Detection Systems
    • 7.2.4. AI-Assisted Surveillance System
    • 7.2.5. Biosensors
    • 7.2.6. Others
  • 7.3. Market Analysis, Insights and Forecast - By End User
    • 7.3.1. Military Forces
    • 7.3.2. Homeland Security
    • 7.3.3. Hospitals & Clinics
    • 7.3.4. Pharmaceutical & Biotech Companies
    • 7.3.5. Virological Research Institutes
  • 7.4. Market Analysis, Insights and Forecast - By Country
    • 7.4.1. U.K.
      • 7.4.1.1. Market Analysis, Insights and Forecast - By End User
        • 7.4.1.1.1. Military Forces
        • 7.4.1.1.2. Homeland Security
        • 7.4.1.1.3. Hospitals & Clinics
        • 7.4.1.1.4. Pharmaceutical & Biotech Companies
        • 7.4.1.1.5. Virological Research Institutes
    • 7.4.2. Germany
      • 7.4.2.1. Market Analysis, Insights and Forecast - By End User
        • 7.4.2.1.1. Military Forces
        • 7.4.2.1.2. Homeland Security
        • 7.4.2.1.3. Hospitals & Clinics
        • 7.4.2.1.4. Pharmaceutical & Biotech Companies
        • 7.4.2.1.5. Virological Research Institutes
    • 7.4.3. France
      • 7.4.3.1. Market Analysis, Insights and Forecast - By End User
        • 7.4.3.1.1. Military Forces
        • 7.4.3.1.2. Homeland Security
        • 7.4.3.1.3. Hospitals & Clinics
        • 7.4.3.1.4. Pharmaceutical & Biotech Companies
        • 7.4.3.1.5. Virological Research Institutes
    • 7.4.4. Russia
      • 7.4.4.1. Market Analysis, Insights and Forecast - By End User
        • 7.4.4.1.1. Military Forces
        • 7.4.4.1.2. Homeland Security
        • 7.4.4.1.3. Hospitals & Clinics
        • 7.4.4.1.4. Pharmaceutical & Biotech Companies
        • 7.4.4.1.5. Virological Research Institutes
    • 7.4.5. Rest of Europe
      • 7.4.5.1. Market Analysis, Insights and Forecast - By End User
        • 7.4.5.1.1. Military Forces
        • 7.4.5.1.2. Homeland Security
        • 7.4.5.1.3. Hospitals & Clinics
        • 7.4.5.1.4. Pharmaceutical & Biotech Companies
        • 7.4.5.1.5. Virological Research Institutes

8. Asia Pacific Biodefense Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Technology
    • 8.1.1. Microwave Heating
    • 8.1.2. UV Light
    • 8.1.3. Gamma Radiation
    • 8.1.4. Cold Plasma
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By System
    • 8.2.1. Digital Biosurveillance Networks
    • 8.2.2. Early Warning Systems
    • 8.2.3. Biohazard Detection Systems
    • 8.2.4. AI-Assisted Surveillance System
    • 8.2.5. Biosensors
    • 8.2.6. Others
  • 8.3. Market Analysis, Insights and Forecast - By End User
    • 8.3.1. Military Forces
    • 8.3.2. Homeland Security
    • 8.3.3. Hospitals & Clinics
    • 8.3.4. Pharmaceutical & Biotech Companies
    • 8.3.5. Virological Research Institutes
  • 8.4. Market Analysis, Insights and Forecast - By Country
    • 8.4.1. China
      • 8.4.1.1. Market Analysis, Insights and Forecast - By End User
        • 8.4.1.1.1. Military Forces
        • 8.4.1.1.2. Homeland Security
        • 8.4.1.1.3. Hospitals & Clinics
        • 8.4.1.1.4. Pharmaceutical & Biotech Companies
        • 8.4.1.1.5. Virological Research Institutes
    • 8.4.2. India
      • 8.4.2.1. Market Analysis, Insights and Forecast - By End User
        • 8.4.2.1.1. Military Forces
        • 8.4.2.1.2. Homeland Security
        • 8.4.2.1.3. Hospitals & Clinics
        • 8.4.2.1.4. Pharmaceutical & Biotech Companies
        • 8.4.2.1.5. Virological Research Institutes
    • 8.4.3. Japan
      • 8.4.3.1. Market Analysis, Insights and Forecast - By End User
        • 8.4.3.1.1. Military Forces
        • 8.4.3.1.2. Homeland Security
        • 8.4.3.1.3. Hospitals & Clinics
        • 8.4.3.1.4. Pharmaceutical & Biotech Companies
        • 8.4.3.1.5. Virological Research Institutes
    • 8.4.4. South Korea
      • 8.4.4.1. Market Analysis, Insights and Forecast - By End User
        • 8.4.4.1.1. Military Forces
        • 8.4.4.1.2. Homeland Security
        • 8.4.4.1.3. Hospitals & Clinics
        • 8.4.4.1.4. Pharmaceutical & Biotech Companies
        • 8.4.4.1.5. Virological Research Institutes
    • 8.4.5. Rest of Asia Pacific
      • 8.4.5.1. Market Analysis, Insights and Forecast - By End User
        • 8.4.5.1.1. Military Forces
        • 8.4.5.1.2. Homeland Security
        • 8.4.5.1.3. Hospitals & Clinics
        • 8.4.5.1.4. Pharmaceutical & Biotech Companies
        • 8.4.5.1.5. Virological Research Institutes

9. Middle East & Africa Biodefense Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Technology
    • 9.1.1. Microwave Heating
    • 9.1.2. UV Light
    • 9.1.3. Gamma Radiation
    • 9.1.4. Cold Plasma
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By System
    • 9.2.1. Digital Biosurveillance Networks
    • 9.2.2. Early Warning Systems
    • 9.2.3. Biohazard Detection Systems
    • 9.2.4. AI-Assisted Surveillance System
    • 9.2.5. Biosensors
    • 9.2.6. Others
  • 9.3. Market Analysis, Insights and Forecast - By End User
    • 9.3.1. Military Forces
    • 9.3.2. Homeland Security
    • 9.3.3. Hospitals & Clinics
    • 9.3.4. Pharmaceutical & Biotech Companies
    • 9.3.5. Virological Research Institutes
  • 9.4. Market Analysis, Insights and Forecast - By Country
    • 9.4.1. Iran
      • 9.4.1.1. Market Analysis, Insights and Forecast - By End User
        • 9.4.1.1.1. Military Forces
        • 9.4.1.1.2. Homeland Security
        • 9.4.1.1.3. Hospitals & Clinics
        • 9.4.1.1.4. Pharmaceutical & Biotech Companies
        • 9.4.1.1.5. Virological Research Institutes
    • 9.4.2. Israel
      • 9.4.2.1. Market Analysis, Insights and Forecast - By End User
        • 9.4.2.1.1. Military Forces
        • 9.4.2.1.2. Homeland Security
        • 9.4.2.1.3. Hospitals & Clinics
        • 9.4.2.1.4. Pharmaceutical & Biotech Companies
        • 9.4.2.1.5. Virological Research Institutes
    • 9.4.3. Saudi Arabia
      • 9.4.3.1. Market Analysis, Insights and Forecast - By End User
        • 9.4.3.1.1. Military Forces
        • 9.4.3.1.2. Homeland Security
        • 9.4.3.1.3. Hospitals & Clinics
        • 9.4.3.1.4. Pharmaceutical & Biotech Companies
        • 9.4.3.1.5. Virological Research Institutes
    • 9.4.4. Turkey
      • 9.4.4.1. Market Analysis, Insights and Forecast - By End User
        • 9.4.4.1.1. Military Forces
        • 9.4.4.1.2. Homeland Security
        • 9.4.4.1.3. Hospitals & Clinics
        • 9.4.4.1.4. Pharmaceutical & Biotech Companies
        • 9.4.4.1.5. Virological Research Institutes
    • 9.4.5. Rest of Middle East & Africa
      • 9.4.5.1. Market Analysis, Insights and Forecast - By End User
        • 9.4.5.1.1. Military Forces
        • 9.4.5.1.2. Homeland Security
        • 9.4.5.1.3. Hospitals & Clinics
        • 9.4.5.1.4. Pharmaceutical & Biotech Companies
        • 9.4.5.1.5. Virological Research Institutes

10. Latin America Biodefense Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Technology
    • 10.1.1. Microwave Heating
    • 10.1.2. UV Light
    • 10.1.3. Gamma Radiation
    • 10.1.4. Cold Plasma
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By System
    • 10.2.1. Digital Biosurveillance Networks
    • 10.2.2. Early Warning Systems
    • 10.2.3. Biohazard Detection Systems
    • 10.2.4. AI-Assisted Surveillance System
    • 10.2.5. Biosensors
    • 10.2.6. Others
  • 10.3. Market Analysis, Insights and Forecast - By End User
    • 10.3.1. Military Forces
    • 10.3.2. Homeland Security
    • 10.3.3. Hospitals & Clinics
    • 10.3.4. Pharmaceutical & Biotech Companies
    • 10.3.5. Virological Research Institutes
  • 10.4. Market Analysis, Insights and Forecast - By Country
    • 10.4.1. Brazil
      • 10.4.1.1. Market Analysis, Insights and Forecast - By End User
        • 10.4.1.1.1. Military Forces
        • 10.4.1.1.2. Homeland Security
        • 10.4.1.1.3. Hospitals & Clinics
        • 10.4.1.1.4. Pharmaceutical & Biotech Companies
        • 10.4.1.1.5. Virological Research Institutes
    • 10.4.2. Argentina
      • 10.4.2.1. Market Analysis, Insights and Forecast - By End User
        • 10.4.2.1.1. Military Forces
        • 10.4.2.1.2. Homeland Security
        • 10.4.2.1.3. Hospitals & Clinics
        • 10.4.2.1.4. Pharmaceutical & Biotech Companies
        • 10.4.2.1.5. Virological Research Institutes
    • 10.4.3. Mexico
      • 10.4.3.1. Market Analysis, Insights and Forecast - By End User
        • 10.4.3.1.1. Military Forces
        • 10.4.3.1.2. Homeland Security
        • 10.4.3.1.3. Hospitals & Clinics
        • 10.4.3.1.4. Pharmaceutical & Biotech Companies
        • 10.4.3.1.5. Virological Research Institutes
    • 10.4.4. Rest of Latin America
      • 10.4.4.1. Market Analysis, Insights and Forecast - By End User
        • 10.4.4.1.1. Military Forces
        • 10.4.4.1.2. Homeland Security
        • 10.4.4.1.3. Hospitals & Clinics
        • 10.4.4.1.4. Pharmaceutical & Biotech Companies
        • 10.4.4.1.5. Virological Research Institutes

11. Competitive Analysis

  • 11.1. Global Market Rank Analysis (2025)
  • 11.2. Competitive Dashboard

12. Company Profiles

  • 12.1. AirBoss Defense Group, Inc. (U.S.)
    • 12.1.1. Overview
    • 12.1.2. Products & services
    • 12.1.3. SWOT Analysis
    • 12.1.4. Recent Developments
    • 12.1.5. Strategies
    • 12.1.6. Financials (Based on Availability)
  • 12.2. Bioquell, An Ecolab Solution (U.S.)
    • 12.2.1. Overview
    • 12.2.2. Products & services
    • 12.2.3. SWOT Analysis
    • 12.2.4. Recent Developments
    • 12.2.5. Strategies
    • 12.2.6. Financials (Based on Availability)
  • 12.3. Bio-Rad Laboratories, Inc. (U.S.)
    • 12.3.1. Overview
    • 12.3.2. Products & services
    • 12.3.3. SWOT Analysis
    • 12.3.4. Recent Developments
    • 12.3.5. Strategies
    • 12.3.6. Financials (Based on Availability)
  • 12.4. BlueDot Inc. (Canada)
    • 12.4.1. Overview
    • 12.4.2. Products & services
    • 12.4.3. SWOT Analysis
    • 12.4.4. Recent Developments
    • 12.4.5. Strategies
    • 12.4.6. Financials (Based on Availability)
  • 12.5. E4life Srl (Australia)
    • 12.5.1. Overview
    • 12.5.2. Products & services
    • 12.5.3. SWOT Analysis
    • 12.5.4. Recent Developments
    • 12.5.5. Strategies
    • 12.5.6. Financials (Based on Availability)
  • 12.6. Emergent BioSolutions Inc. (U.S.)
    • 12.6.1. Overview
    • 12.6.2. Products & services
    • 12.6.3. SWOT Analysis
    • 12.6.4. Recent Developments
    • 12.6.5. Strategies
    • 12.6.6. Financials (Based on Availability)
  • 12.7. SIGA Technologies, Inc. (U.S.)
    • 12.7.1. Overview
    • 12.7.2. Products & services
    • 12.7.3. SWOT Analysis
    • 12.7.4. Recent Developments
    • 12.7.5. Strategies
    • 12.7.6. Financials (Based on Availability)
  • 12.8. Dynavax Technologies (U.S.)
    • 12.8.1. Overview
    • 12.8.2. Products & services
    • 12.8.3. SWOT Analysis
    • 12.8.4. Recent Developments
    • 12.8.5. Strategies
    • 12.8.6. Financials (Based on Availability)
  • 12.9. Alnylam Pharmaceuticals, Inc. (U.S.)
    • 12.9.1. Overview
    • 12.9.2. Products & services
    • 12.9.3. SWOT Analysis
    • 12.9.4. Recent Developments
    • 12.9.5. Strategies
    • 12.9.6. Financials (Based on Availability)
  • 12.10. Ichor Medical Systems Inc. (U.S.)
    • 12.10.1. Overview
    • 12.10.2. Products & services
    • 12.10.3. SWOT Analysis
    • 12.10.4. Recent Developments
    • 12.10.5. Strategies
    • 12.10.6. Financials (Based on Availability)
  • 12.11. Bavarian Nordic A/S (Denmark)
    • 12.11.1. Overview
    • 12.11.2. Products & services
    • 12.11.3. SWOT Analysis
    • 12.11.4. Recent Developments
    • 12.11.5. Strategies
    • 12.11.6. Financials (Based on Availability)
  • 12.12. SKAN AG (Switzerland)
    • 12.12.1. Overview
    • 12.12.2. Products & services
    • 12.12.3. SWOT Analysis
    • 12.12.4. Recent Developments
    • 12.12.5. Strategies
    • 12.12.6. Financials (Based on Availability)
  • 12.13. Smiths Detection Group Ltd (U.K.)
    • 12.13.1. Overview
    • 12.13.2. Products & services
    • 12.13.3. SWOT Analysis
    • 12.13.4. Recent Developments
    • 12.13.5. Strategies
    • 12.13.6. Financials (Based on Availability)
  • 12.14. Parsons Corporation (U.S.)
    • 12.14.1. Overview
    • 12.14.2. Products & services
    • 12.14.3. SWOT Analysis
    • 12.14.4. Recent Developments
    • 12.14.5. Strategies
    • 12.14.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Biodefense Market, (USD Bn) Forecast, By Technology, 2021-2034
  • Table 2: Global Biodefense Market, (USD Bn) Forecast, By System, 2021-2034
  • Table 3: Global Biodefense Market, (USD Bn) Forecast, By End User, 2021-2034
  • Table 4: Global Biodefense Market (USD Bn) Forecast, By Region, 2021-2034
  • Table 5: North America Biodefense Market, (USD Bn) Forecast, By Technology, 2021-2034
  • Table 6: North America Biodefense Market, (USD Bn) Forecast, By System, 2021-2034
  • Table 7: North America Biodefense Market, (USD Bn) Forecast, By End User, 2021-2034
  • Table 8: North America Biodefense Market (USD Bn) Forecast, By Country, 2021-2034
  • Table 9: U.S. Biodefense Market, (USD Bn) Forecast, By End User, 2021-2034
  • Table 10: Canada Biodefense Market, (USD Bn) Forecast, By End User, 2021-2034
  • Table 11: Europe Biodefense Market, (USD Bn) Forecast, By Technology, 2021-2034
  • Table 12: Europe Biodefense Market, (USD Bn) Forecast, By System, 2021-2034
  • Table 13: Europe Biodefense Market, (USD Bn) Forecast, By End User, 2021-2034
  • Table 14: Europe Biodefense Market (USD Bn) Forecast, By Country, 2021-2034
  • Table 15: U.K. Biodefense Market, (USD Bn) Forecast, By End User, 2021-2034
  • Table 16: Germany Biodefense Market, (USD Bn) Forecast, By End User, 2021-2034
  • Table 17: France Biodefense Market, (USD Bn) Forecast, By End User, 2021-2034
  • Table 18: Russia Biodefense Market, (USD Bn) Forecast, By End User, 2021-2034
  • Table 19: Rest of Europe Biodefense Market, (USD Bn) Forecast, By End User, 2021-2034
  • Table 20: Asia Pacific Biodefense Market, (USD Bn) Forecast, By Technology, 2021-2034
  • Table 21: Asia Pacific Biodefense Market, (USD Bn) Forecast, By System, 2021-2034
  • Table 22: Asia Pacific Biodefense Market, (USD Bn) Forecast, By End User, 2021-2034
  • Table 23: Asia Pacific Biodefense Market (USD Bn) Forecast, By Country, 2021-2034
  • Table 24: China Biodefense Market, (USD Bn) Forecast, By End User, 2021-2034
  • Table 25: India Biodefense Market, (USD Bn) Forecast, By End User, 2021-2034
  • Table 26: Japan Biodefense Market, (USD Bn) Forecast, By End User, 2021-2034
  • Table 27: South Korea Biodefense Market, (USD Bn) Forecast, By End User, 2021-2034
  • Table 28: Rest of Asia Pacific Biodefense Market, (USD Bn) Forecast, By End User, 2021-2034
  • Table 29: Middle East & Africa Biodefense Market, (USD Bn) Forecast, By Technology, 2021-2034
  • Table 30: Middle East & Africa Biodefense Market, (USD Bn) Forecast, By System, 2021-2034
  • Table 31: Middle East & Africa Biodefense Market, (USD Bn) Forecast, By End User, 2021-2034
  • Table 32: Middle East & Africa Biodefense Market (USD Bn) Forecast, By Country, 2021-2034
  • Table 33: Iran Biodefense Market, (USD Bn) Forecast, By End User, 2021-2034
  • Table 34: Israel Biodefense Market, (USD Bn) Forecast, By End User, 2021-2034
  • Table 35: Saudi Arabia Biodefense Market, (USD Bn) Forecast, By End User, 2021-2034
  • Table 36: Turkey Biodefense Market, (USD Bn) Forecast, By End User, 2021-2034
  • Table 37: Rest of Middle East & Africa Biodefense Market, (USD Bn) Forecast, By End User, 2021-2034
  • Table 38: Latin America Biodefense Market, (USD Bn) Forecast, By Technology, 2021-2034
  • Table 39: Latin America Biodefense Market, (USD Bn) Forecast, By System, 2021-2034
  • Table 40: Latin America Biodefense Market, (USD Bn) Forecast, By End User, 2021-2034
  • Table 41: Latin America Biodefense Market (USD Bn) Forecast, By Country, 2021-2034
  • Table 42: Brazil Biodefense Market, (USD Bn) Forecast, By End User, 2021-2034
  • Table 43: Argentina Biodefense Market, (USD Bn) Forecast, By End User, 2021-2034
  • Table 44: Mexico Biodefense Market, (USD Bn) Forecast, By End User, 2021-2034
  • Table 45: Rest of Latin America Biodefense Market, (USD Bn) Forecast, By End User, 2021-2034

List of Figures

  • Figure 1: Global Biodefense Market Revenue Breakdown (USD Billion, %) By Region, 2025 & 2034
  • Figure 2: Global Biodefense Market (%) Breakdown By Technology, 2025 & 2034
  • Figure 3: Global Biodefense Market (USD Bn) Breakdown By Microwave Heating, 2021-2034
  • Figure 4: Global Biodefense Market (USD Bn) Breakdown By UV Light, 2021-2034
  • Figure 5: Global Biodefense Market (USD Bn) Breakdown By Gamma Radiation, 2021-2034
  • Figure 6: Global Biodefense Market (USD Bn) Breakdown By Cold Plasma, 2021-2034
  • Figure 7: Global Biodefense Market (USD Bn) Breakdown By Others, 2021-2034
  • Figure 8: Global Biodefense Market (%) Breakdown By System, 2025 & 2034
  • Figure 9: Global Biodefense Market (USD Bn) Breakdown By Digital Biosurveillance Networks, 2021-2034
  • Figure 10: Global Biodefense Market (USD Bn) Breakdown By Early Warning Systems, 2021-2034
  • Figure 11: Global Biodefense Market (USD Bn) Breakdown By Biohazard Detection Systems, 2021-2034
  • Figure 12: Global Biodefense Market (USD Bn) Breakdown By AI-Assisted Surveillance System, 2021-2034
  • Figure 13: Global Biodefense Market (USD Bn) Breakdown By Biosensors, 2021-2034
  • Figure 14: Global Biodefense Market (USD Bn) Breakdown By Others, 2021-2034
  • Figure 15: Global Biodefense Market (%) Breakdown By End User, 2025 & 2034
  • Figure 16: Global Biodefense Market (USD Bn) Breakdown By Military Forces, 2021-2034
  • Figure 17: Global Biodefense Market (USD Bn) Breakdown By Homeland Security, 2021-2034
  • Figure 18: Global Biodefense Market (USD Bn) Breakdown By Hospitals & Clinics, 2021-2034
  • Figure 19: Global Biodefense Market (USD Bn) Breakdown By Pharmaceutical & Biotech Companies, 2021-2034
  • Figure 20: Global Biodefense Market (USD Bn) Breakdown By Virological Research Institutes, 2021-2034
  • Figure 21: Global Biodefense Market Share (%) By Region, 2025 & 2034
  • Figure 22: North America Biodefense Market Value (USD Bn) By Technology, 2025 & 2034
  • Figure 23: North America Biodefense Market Value Share (%) By Technology, 2025
  • Figure 24: North America Biodefense Market Value (USD Bn) By System, 2025 & 2034
  • Figure 25: North America Biodefense Market Value Share (%) By System, 2025
  • Figure 26: North America Biodefense Market Value (USD Bn) By End User, 2025 & 2034
  • Figure 27: North America Biodefense Market Value Share (%) By End User, 2025
  • Figure 28: North America Biodefense Market Value (USD Bn) By Country, 2025 & 2034
  • Figure 29: North America Biodefense Value Share (%) By Country, 2025
  • Figure 30: U.S. Biodefense Market Value (USD Bn) By End User, 2025 & 2034
  • Figure 31: U.S. Biodefense Market Value Share (%) By End User, 2025
  • Figure 32: Canada Biodefense Market Value (USD Bn) By End User, 2025 & 2034
  • Figure 33: Canada Biodefense Market Value Share (%) By End User, 2025
  • Figure 34: Europe Biodefense Market Value (USD Bn) By Technology, 2025 & 2034
  • Figure 35: Europe Biodefense Market Value Share (%) By Technology, 2025
  • Figure 36: Europe Biodefense Market Value (USD Bn) By System, 2025 & 2034
  • Figure 37: Europe Biodefense Market Value Share (%) By System, 2025
  • Figure 38: Europe Biodefense Market Value (USD Bn) By End User, 2025 & 2034
  • Figure 39: Europe Biodefense Market Value Share (%) By End User, 2025
  • Figure 40: Europe Biodefense Market Value (USD Bn) By Country, 2025 & 2034
  • Figure 41: Europe Biodefense Value Share (%) By Country, 2025
  • Figure 42: U.K. Biodefense Market Value (USD Bn) By End User, 2025 & 2034
  • Figure 43: U.K. Biodefense Market Value Share (%) By End User, 2025
  • Figure 44: Germany Biodefense Market Value (USD Bn) By End User, 2025 & 2034
  • Figure 45: Germany Biodefense Market Value Share (%) By End User, 2025
  • Figure 46: France Biodefense Market Value (USD Bn) By End User, 2025 & 2034
  • Figure 47: France Biodefense Market Value Share (%) By End User, 2025
  • Figure 48: Russia Biodefense Market Value (USD Bn) By End User, 2025 & 2034
  • Figure 49: Russia Biodefense Market Value Share (%) By End User, 2025
  • Figure 50: Rest of Europe Biodefense Market Value (USD Bn) By End User, 2025 & 2034
  • Figure 51: Rest of Europe Biodefense Market Value Share (%) By End User, 2025
  • Figure 52: Asia Pacific Biodefense Market Value (USD Bn) By Technology, 2025 & 2034
  • Figure 53: Asia Pacific Biodefense Market Value Share (%) By Technology, 2025
  • Figure 54: Asia Pacific Biodefense Market Value (USD Bn) By System, 2025 & 2034
  • Figure 55: Asia Pacific Biodefense Market Value Share (%) By System, 2025
  • Figure 56: Asia Pacific Biodefense Market Value (USD Bn) By End User, 2025 & 2034
  • Figure 57: Asia Pacific Biodefense Market Value Share (%) By End User, 2025
  • Figure 58: Asia Pacific Biodefense Market Value (USD Bn) By Country, 2025 & 2034
  • Figure 59: Asia Pacific Biodefense Value Share (%) By Country, 2025
  • Figure 60: China Biodefense Market Value (USD Bn) By End User, 2025 & 2034
  • Figure 61: China Biodefense Market Value Share (%) By End User, 2025
  • Figure 62: India Biodefense Market Value (USD Bn) By End User, 2025 & 2034
  • Figure 63: India Biodefense Market Value Share (%) By End User, 2025
  • Figure 64: Japan Biodefense Market Value (USD Bn) By End User, 2025 & 2034
  • Figure 65: Japan Biodefense Market Value Share (%) By End User, 2025
  • Figure 66: South Korea Biodefense Market Value (USD Bn) By End User, 2025 & 2034
  • Figure 67: South Korea Biodefense Market Value Share (%) By End User, 2025
  • Figure 68: Rest of Asia Pacific Biodefense Market Value (USD Bn) By End User, 2025 & 2034
  • Figure 69: Rest of Asia Pacific Biodefense Market Value Share (%) By End User, 2025
  • Figure 70: Middle East & Africa Biodefense Market Value (USD Bn) By Technology, 2025 & 2034
  • Figure 71: Middle East & Africa Biodefense Market Value Share (%) By Technology, 2025
  • Figure 72: Middle East & Africa Biodefense Market Value (USD Bn) By System, 2025 & 2034
  • Figure 73: Middle East & Africa Biodefense Market Value Share (%) By System, 2025
  • Figure 74: Middle East & Africa Biodefense Market Value (USD Bn) By End User, 2025 & 2034
  • Figure 75: Middle East & Africa Biodefense Market Value Share (%) By End User, 2025
  • Figure 76: Middle East & Africa Biodefense Market Value (USD Bn) By Country, 2025 & 2034
  • Figure 77: Middle East & Africa Biodefense Value Share (%) By Country, 2025
  • Figure 78: Iran Biodefense Market Value (USD Bn) By End User, 2025 & 2034
  • Figure 79: Iran Biodefense Market Value Share (%) By End User, 2025
  • Figure 80: Israel Biodefense Market Value (USD Bn) By End User, 2025 & 2034
  • Figure 81: Israel Biodefense Market Value Share (%) By End User, 2025
  • Figure 82: Saudi Arabia Biodefense Market Value (USD Bn) By End User, 2025 & 2034
  • Figure 83: Saudi Arabia Biodefense Market Value Share (%) By End User, 2025
  • Figure 84: Turkey Biodefense Market Value (USD Bn) By End User, 2025 & 2034
  • Figure 85: Turkey Biodefense Market Value Share (%) By End User, 2025
  • Figure 86: Rest of Middle East & Africa Biodefense Market Value (USD Bn) By End User, 2025 & 2034
  • Figure 87: Rest of Middle East & Africa Biodefense Market Value Share (%) By End User, 2025
  • Figure 88: Latin America Biodefense Market Value (USD Bn) By Technology, 2025 & 2034
  • Figure 89: Latin America Biodefense Market Value Share (%) By Technology, 2025
  • Figure 90: Latin America Biodefense Market Value (USD Bn) By System, 2025 & 2034
  • Figure 91: Latin America Biodefense Market Value Share (%) By System, 2025
  • Figure 92: Latin America Biodefense Market Value (USD Bn) By End User, 2025 & 2034
  • Figure 93: Latin America Biodefense Market Value Share (%) By End User, 2025
  • Figure 94: Latin America Biodefense Market Value (USD Bn) By Country, 2025 & 2034
  • Figure 95: Latin America Biodefense Value Share (%) By Country, 2025
  • Figure 96: Brazil Biodefense Market Value (USD Bn) By End User, 2025 & 2034
  • Figure 97: Brazil Biodefense Market Value Share (%) By End User, 2025
  • Figure 98: Argentina Biodefense Market Value (USD Bn) By End User, 2025 & 2034
  • Figure 99: Argentina Biodefense Market Value Share (%) By End User, 2025
  • Figure 100: Mexico Biodefense Market Value (USD Bn) By End User, 2025 & 2034
  • Figure 101: Mexico Biodefense Market Value Share (%) By End User, 2025
  • Figure 102: Rest of Latin America Biodefense Market Value (USD Bn) By End User, 2025 & 2034
  • Figure 103: Rest of Latin America Biodefense Market Value Share (%) By End User, 2025
  • Figure 104: Global Biodefense Market Rank Analysis, By Key Players, 2025